Literature DB >> 34531266

18F-DCFPyL PET Acquisition, Interpretation, and Reporting: Suggestions After Food and Drug Administration Approval.

Hong Song1, Andrei Iagaru2, Steven P Rowe3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34531266     DOI: 10.2967/jnumed.121.262989

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  3 in total

Review 1.  Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer.

Authors:  Jiaxian Chen; Lin Qi; Yongxiang Tang; Guyu Tang; Yu Gan; Yi Cai
Journal:  Front Cell Dev Biol       Date:  2022-08-12

Review 2.  The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer.

Authors:  Adam M Kase; Winston Tan; John A Copland; Hancheng Cai; Ephraim E Parent; Ravi A Madan
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

Review 3.  Radiolabeled PSMA Inhibitors.

Authors:  Oliver C Neels; Klaus Kopka; Christos Liolios; Ali Afshar-Oromieh
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.